VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

TMates Weightloss Semaglutide reviews reveal how users are losing weight with this telehealth prescription service—see if it ...

More people are reporting experiencing potentially dangerous side effects after using slimming drugs, the national toxicology ...

Ozempic may have serious side effects, including thyroid cancer and problems with the pancreas, gallbladder, kidneys, and ...

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

The MHRA has revealed it's received more than 560 reports of acute pancreatitis in patients taking GLP-1 injections since ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

Blockbuster weight-loss shots like Ozempic, Wegovy and Victoza may have an unexpected side effect impacting as many as ...

It can affect 1 in 100 patientsThe likes of Mounjaro, Ozempic and Wegovy are being associated with an inflamed ...